Physician profile
Amy E Bailey
NPI 1427277755
$1,294.36
in general payments reported to CMS, 2019-2025
26 companies · $236 in 2025
The $236 reported for 2025 was more than what 78% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $106 · 2021: $289 · 2022: $269 · 2023: $61.55 · 2024: $163 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $216.51 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $163.67 | 2021-2025 | Trintellix |
| Novo Nordisk INC | $139.25 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.21 | 2021-2022 | |
| Genentech USA, INC. | $77.38 | 2019-2020 | |
| Amgen INC. | $67.70 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $55.15 | 2019 | |
| Abbvie INC. | $53.33 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $45.56 | 2019-2024 | Farxiga |
| Pfizer INC. | $44.57 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $35.78 | 2025 | Koselugo |
| Abbott Laboratories | $34.81 | 2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.11 | 2025 | Caplyta |
| Medtronic, INC. | $30.70 | 2024 | Intellis Adaptivestim |
| Boston Scientific Corporation | $26.67 | 2025 | Watchman Flx |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $24.69 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $24.60 | 2019-2021 | |
| Lilly USA, LLC | $23.89 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.24 | 2022 | |
| Biogen, INC. | $20.33 | 2020 | |
| Dexcom, INC. | $13.76 | 2021 | |
| Organogenesis INC. | $13.14 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $12.68 | 2021 | |
| Allergan, INC. | $11.80 | 2020 | |
| Nestle Healthcare Nutrition INC. | $11.63 | 2021 | |
| Eisai INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.